Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. — Investor Relations & Filings
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. provides integrated research, development, and manufacturing services for drug product development. The company specializes in formulation technology, analytical chemistry, and process optimization for chemical drugs. Its service portfolio encompasses pre-formulation studies, dosage form design, stability testing, and clinical trial material production. Bio-Sincerity supports the development of both generic medications and innovative small molecule therapeutics, offering technical expertise in complex delivery systems and regulatory submission documentation. By leveraging advanced laboratory facilities and pilot production capabilities, the organization facilitates the transition of drug candidates from laboratory scale to commercial manufacturing, focusing on technical precision and quality management systems.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 非经营性资金占用及其他关联资金往来情况的专项审计说明 | 2026-04-23 | Chinese | |
| 董事会对独立董事独立性自查情况的专项报告 | 2026-04-23 | Chinese | |
| 独立董事2025年度述职报告（黄志雄） | 2026-04-23 | Chinese | |
| 独立董事2025年度述职报告（袁弘） | 2026-04-23 | Chinese | |
| 2025年度内部控制评价报告 | 2026-04-23 | Chinese | |
| 2025年度非经营性资金占用及其他关联资金往来情况汇总表 | 2026-04-23 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 40011477 | 非经营性资金占用及其他关联资金往来情况的专项审计说明 | 2026-04-23 | Chinese | ||
| 40011443 | 董事会对独立董事独立性自查情况的专项报告 | 2026-04-23 | Chinese | ||
| 40011433 | 独立董事2025年度述职报告（黄志雄） | 2026-04-23 | Chinese | ||
| 40011432 | 独立董事2025年度述职报告（袁弘） | 2026-04-23 | Chinese | ||
| 40011429 | 2025年度内部控制评价报告 | 2026-04-23 | Chinese | ||
| 40011428 | 2025年度非经营性资金占用及其他关联资金往来情况汇总表 | 2026-04-23 | Chinese | ||
| 40011417 | 2025年度董事会工作报告 | 2026-04-23 | Chinese | ||
| 40011416 | 关于计提信用减值损失及资产减值损失的公告 | 2026-04-23 | Chinese | ||
| 40011414 | 2025年年度募集资金年度存放、管理与使用情况鉴证报告 | 2026-04-23 | Chinese | ||
| 40011410 | 审计委员会对会计师事务所2025年度履职情况评估报告及履行监督职责情况报告 | 2026-04-23 | Chinese | ||
| 40011407 | 独立董事2025年度述职报告（胡富强-已离任） | 2026-04-23 | Chinese | ||
| 40011406 | 独立董事2025年度述职报告（任成-已离任） | 2026-04-23 | Chinese | ||
| 40011404 | 2025年内部控制审计报告 | 2026-04-23 | Chinese | ||
| 40011401 | 2025年度关于营业收入扣除情况的专项核查意见 | 2026-04-23 | Chinese | ||
| 40011392 | 关于员工战略配售资管计划减持期限届满暨实施情况的公告 | 2026-04-07 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56048/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56048 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56048 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56048 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56048}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (id: 56048)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.